Related Experiment Videos

Tubular expression of intercellular adhesion molecule-1 during renal allograft rejection

R J Faull1, G R Russ

  • 1Transplantation Immunology Laboratory, Queen Elizabeth Hospital, Woodville, South Australia.

Transplantation
|August 1, 1989
PubMed

Insights

Intercellular adhesion molecule-1 (ICAM-1) is upregulated on kidney allografts during rejection, appearing on tubular cells alongside HLA class II antigens. However, its presence in non-rejecting grafts limits clinical monitoring utility.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Cell Adhesion Molecules

Background:

  • Cell adhesion molecules are critical for immune responses.
  • Intercellular adhesion molecule-1 (ICAM-1) is a key adhesion molecule involved in immune cell interactions.
  • Understanding ICAM-1 expression in kidney allografts is important for assessing transplant outcomes.

Purpose of the Study:

  • To examine the expression of ICAM-1 in normal and allografted kidneys.
  • To compare ICAM-1 expression with HLA class II antigens during kidney transplantation.
  • To evaluate the potential of ICAM-1 and HLA class II as biomarkers for kidney allograft rejection.

Main Methods:

  • Utilized a specific monoclonal antibody against ICAM-1.
  • Employed an indirect immunoperoxidase technique for ICAM-1 detection.
  • Analyzed kidney biopsies from normal, pre-implantation, and post-transplantation allografts.

Main Results:

  • In normal kidneys, ICAM-1 was primarily expressed on vascular endothelial cells (VEC) and parietal epithelium.
  • Allograft rejection was associated with de novo ICAM-1 expression on renal tubular epithelial cells, mirroring HLA class II antigen expression.
  • Increased endothelial ICAM-1 and HLA class II expression was observed during rejection.
  • Tubular expression of ICAM-1 and HLA class II in some non-rejecting biopsies limited their clinical utility for monitoring.

Conclusions:

  • ICAM-1 expression on renal tubular cells parallels HLA class II antigen expression during kidney allograft rejection.
  • The upregulation of ICAM-1 and HLA class II is likely cytokine-mediated but may involve other mechanisms.
  • Monitoring ICAM-1 and HLA class II in post-transplant biopsies has limited clinical usefulness due to expression in non-rejecting grafts.

Related Concept Videos